Visit us at DDW - Booth 3620

PancraGEN® is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts, helping you to optimally manage each individual patient.

By adding PancraGen to first line testing, you can more confidently choose appropriate surveillance strategies or surgical options for patients with pancreatic cysts.

PancraGEN Overview

Learn more about PancraGEN

The Pancreatic Cyst Dilemma

Pancreatic cancer is a serious but rare condition.

Even when diagnosed early, pancreatic cancer has a poor prognosis. Surgery is commonly performed as a cautious approach to treat a suspicious cyst. However surgery comes with risks, including life-long patient morbidities and even mortality.

Yet, recent research has shown that the risk of malignancy in cysts is lower than previously thought. Treatment plans are evolving from surgery to watchful waiting in recognition that many cysts are benign and will remain benign.

Recent studies have shown that up to 80% of surgeries reveal indolent cysts that didn’t necessarily require surgery.5,6

Today’s standard of care – imaging, CEA, Amylase, Cytology, and patient risk factors – does not always give you the full picture about the risk of malignancy of a pancreatic cyst.1

What if we could help better predict whether a cyst will become malignant or remain benign?

Learn more about the Dilemma

Seeking Clarity

PancraGEN – the pancreatic cyst risk classifier – can help you answer these questions:

Is this cyst benign or aggressive today?

What is the likelihood that the cyst will progress to cancer?

How do I monitor this patient and what do I do next?

Learn more about PancraGEN

Pancreatic Cyst Dilemmas:
From Guidelines to Molecular Markers

Webinar Excerpt
Risk Stratification

View Webinar Excerpt

Webinar Faculty

Limitations and Disclaimers1

Although PancraGEN is highly specific for malignancy, some malignant cysts may not be detected. There may also be individuals who are falsely identified as having a malignant cyst. Diagnosis and appropriate patient management are the responsibility of the referring physician or healthcare provider.

References

  1. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
  2. V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
  3. BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
  4. Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
  5. Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
  6. Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017
  7. Kushnir VM, Mullady DK, Das K, et al. J Clin Gastroenterol. 2019;53(9):686-692. DOI: 10.1097/MCG.0000000000001118.
  8. Gonda TA, Viterbo D, Gausman V, et al. Clin Gastroenterol Hepatol. 2017;15:913-919.
  9. Data on File.